Schizophrenia and L-745,870, a novel dopamine D4 receptor antagonist

Trends in Pharmacological Sciences

Volumn 18, Issue 6, 1997, Pages 186-188

  Bristow, L J ^a   Kramer, M S ^b   Kulagowski, J ^a   Patel, S ^a   Ragan, C I ^a   Seabrook, G R ^a  

^a Merck Sharp & Dohme Limited   (United Kingdom)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 [[4 (4 CHLOROPHENYL) 1 PIPERAZINYL]METHYL] 1H PYRROLO[2,3 B]PYRIDINE; DOPAMINE 4 RECEPTOR; DOPAMINE RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG;

DRUG EFFICACY; DRUG RECEPTOR BINDING; EXTRAPYRAMIDAL SYMPTOM; HUMAN; PRIORITY JOURNAL; RECEPTOR AFFINITY; REVIEW; SCHIZOPHRENIA;

EID: 0030848168     PISSN: 01656147     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0165-6147(97)90618-0     Document Type: Article

References (11)

1. Van Tol H. H. M. et al. Nature. 350:1991;610-614.
2. O'Malley K. L., Harmon S., Tang L., Todd R. D. The New Biologist. 4(2):1992;137-146.
3. Seeman P., Guan H-C., Van Tol H. H. M. Nature. 365:1993;441-445.
4. Reynolds G. P., Mason S. L. J. Neurochem. 63:1994;1576-1577.
5. McAllister G. et al. J. Recept. Signal Trans. Res. 15:1995;267-281.
6. Kulagowski J. J. et al. J. Med. Chem. 39:1996;1941-1942.
7. Seabrook G. R. et al. Br. J. Pharmacol. 112:1994;728-734.
8. Bowery B. J., Rothwell L. A., Seabrook G. R. Br. J. Pharmacol. 112:1994;873-880.
9. Patel S. et al. Br. J. Pharmacol. 119:1996;30P.
10. Bristow L. J. et al. Br. J. Pharmacol. 119:1996;210P.
11. Kramer, M. S., Last, B., Getson, A. and Reines, S. A. Arch. Gen. Psychiatry in press.